Key facts
- This page summarizes Anthony Prentice's Form 4 filing for Sema4 Holdings Corp. (WGS).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 26 Jul 2021, 18:39.
Anthony Prentice - 22 Jul 2021 Form 4 Insider Report for Sema4 Holdings Corp. (WGS)
- Reporting relationship
- Chief Product Officer
- Issuer ticker
- WGS
- Reported as of
- 22 Jul 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Jul 2021, 18:39:15 UTC
- Next SEC filing
- 05 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Clark, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Anthony Prentice filed Form 4 for Sema4 Holdings Corp. (WGS) on 26 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
WGSWW
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +1,733,674
- Change %
- Price
- Shares after
- 1,733,674
- Date
- 22 Jul 2021
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 1,733,674
- Exercise price
- $0.1529
- Footnotes
- F1, F2
WGSWW
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +449,871
- Change %
- Price
- Shares after
- 449,871
- Date
- 22 Jul 2021
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 449,871
- Exercise price
- $0.7659
- Footnotes
- F1, F2
WGSWW
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +196,666
- Change %
- Price
- Shares after
- 196,666
- Date
- 22 Jul 2021
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 196,666
- Exercise price
- $0.7659
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Footnote F2
Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.
SEC remarks
The merger agreement provides that certain former stockholders and equity award holders of Sema4 will receive additional shares of the Issuer's Class A common stock and awards of restricted stock units upon the achievement of certain vesting conditions.